98 related articles for article (PubMed ID: 17559739)
1. The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin.
Devine EB; Cross JT; Kowdley KV; Sullivan SD
Curr Med Res Opin; 2007 Jun; 23(6):1463-72. PubMed ID: 17559739
[TBL] [Abstract][Full Text] [Related]
2. Anemia during treatment of hepatitis C in HIV-infected patients.
Lo Re V; Kostman JR
AIDS Read; 2004 Oct; 14(10):555-7, 562, 565-71. PubMed ID: 15510392
[TBL] [Abstract][Full Text] [Related]
3. Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C.
Sharvadze L; Tsertsvadze T; Gochitashvili N; Kakabadze T; Dolmazashvili E
Georgian Med News; 2006 Aug; (137):62-5. PubMed ID: 16980747
[TBL] [Abstract][Full Text] [Related]
4. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
[TBL] [Abstract][Full Text] [Related]
5. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life.
Lidgren M; Hollander A; Weiland O; Jönsson B
Scand J Gastroenterol; 2007 Jul; 42(7):867-77. PubMed ID: 17558912
[TBL] [Abstract][Full Text] [Related]
6. High dose of erythropoietin in management of interferon/ribavirin induced anemia.
Ucciferri C; Falasca K; Mancino P; De Tullio D; Pizzigallo E; Vecchiet J
Hepatogastroenterology; 2007 Dec; 54(80):2181-3. PubMed ID: 18265628
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.
Chapko MK; Dominitz JA
Aliment Pharmacol Ther; 2006 Oct; 24(7):1067-77. PubMed ID: 16984501
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand.
Roungrong J; Teerawattananon Y; Chaikledkaew U
J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S119-25. PubMed ID: 19255987
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
10. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C.
Dar Santos AE; Partovi N; Ford JA; Yoshida EM
Ann Pharmacother; 2007 Feb; 41(2):268-75. PubMed ID: 17299014
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events.
Smith JP
Pharmacotherapy; 2008 Sep; 28(9):1151-61. PubMed ID: 18752386
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.
Hedenus M; Näsman P; Liwing J
J Clin Pharm Ther; 2008 Aug; 33(4):365-74. PubMed ID: 18613854
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
Choy CK; Spencer AP; Nappi JM
Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
[TBL] [Abstract][Full Text] [Related]
15. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia.
Grattagliano I; Russmann S; Palmieri VO; Portincasa P; Palasciano G; Lauterburg BH
Clin Pharmacol Ther; 2005 Oct; 78(4):422-32. PubMed ID: 16198661
[TBL] [Abstract][Full Text] [Related]
16. Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Yachimski P; Chung RT
AIDS Read; 2004 Oct; 14(10):568-9. PubMed ID: 15510393
[No Abstract] [Full Text] [Related]
17. Evaluating treatment of hepatitis C for hemolytic anemia management.
DebRoy S; Kribs-Zaleta C; Mubayi A; Cardona-Meléndez GM; Medina-Rios L; Kang M; Diaz E
Math Biosci; 2010 Jun; 225(2):141-55. PubMed ID: 20303990
[TBL] [Abstract][Full Text] [Related]
18. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
Devine EB; Kowdley KV; Veenstra DL; Sullivan SD
Value Health; 2001; 4(5):376-84. PubMed ID: 11705128
[TBL] [Abstract][Full Text] [Related]
19. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.
Rivkin AM; Chawla S
Pharmacotherapy; 2005 Jun; 25(6):862-75. PubMed ID: 15927905
[TBL] [Abstract][Full Text] [Related]
20. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
